Research Associate
BrainChild Bio
Research Associate
BrainChild Bio
CAR T therapies targeting CNS tumors
Salary Range: 90000 to 105000 (Currency: USD) (Pay period: per-year-salary)
BrainChild Bio is seeking an enthusiastic, self-driven Research Associate to join our Process Core team within Process Development. The successful candidate will be part of a team of associate scientists and engineers that design, execute, and analyze experiments supporting process development studies, material generation runs, automation efforts, and process characterization activities. This position requires positive, collaborative abilities, clear organizational skills, and excellent prioritization to help drive timely delivery of high quality experimental data to advance programs and support regulatory filings. If you are creative problem solver that thrives while working in a fast-paced, highly collaborative environment, come join us!
Responsibilities:
• Design and execute experiments to support cell therapy process development including Design of Experiments (DOE) studies to efficiently optimize unit operations
• Support planning activities prior to study execution including batch record authoring and reagent/material preparation
• Support troubleshooting during study execution and evaluation of potential impacts
• Document experiments in a timely and thorough manner using electronic laboratory notebooks
• Perform statistical data analysis using JMP software
• Author study reports detailing experimental work and summarizing results
• Present experimental findings to cross-functional teams following study completion
Qualifications:
• BS in Bioengineering, Chemical Engineering, Biology, or other related discipline
• 2+ years of relevant laboratory experience. Prior experience in cell therapy industry preferred.
• Proficiency with mammalian cell culture sterile technique
• Proficiency with lab electronic notebook and report writing
• Flexibility with work schedule (i.e., occasional weekend work)
CAR T therapies targeting CNS tumors
What BrainChild Bio does: It develops CAR T cell therapies to treat tumors in the central nervous system, focusing on children first and then expanding to adults with glioblastoma. How its product works: The lead therapy, BCB-276, uses a patient’s own T cells engineered to target B7-H3, and is given directly into the cerebrospinal fluid to reach brain and spine tumors. The company is also advancing a triple-targeting candidate, BCB-214, toward initial glioblastoma testing. How it differs from competitors: BrainChild Bio relies on autologous CAR T cells delivered locoregionally into CSF, with technology licensed from Seattle Children’s and strong ties to that institution, aiming at pediatric DIPG and other CNS cancers. What its goal is: To complete the Phase 2 ILLUMINATE trial to support a future regulatory filing for BCB-276 and to broaden its pipeline for CNS tumors, including early work on glioblastoma, supported by a recent $116 million Series A.
Explore more opportunities at BrainChild Bio